Regulation of porphyrin synthesis and photodynamic therapy in heavy metal intoxication

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 25, Issue 1-2, 2006, Pages 145-158

  Grinblat, Borislava ^a   Pour, Nir ^a   Malik, Zvi ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

ALA PDT; Gallium; Lead; PBGD; Porphyrin

Indexed keywords

AMINOLEVULINIC ACID; GALLIUM; LEAD; PORPHOBILINOGEN DEAMINASE; PORPHOBILINOGEN SYNTHASE; PORPHYRIN;

ANIMAL CELL; ARTICLE; CANCER THERAPY; CELL COUNT; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; HEAVY METAL POISONING; HUMAN; HUMAN CELL; LEAD POISONING; NEUROBLASTOMA CELL; NONHUMAN; PHEOCHROMOCYTOMA CELL; PHOTODYNAMIC THERAPY; PORPHYRIN METABOLISM; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE;

ANIMALIA;

EID: 33644748404     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.v25.i1-2.80     Document Type: Article

References (34)

1. Zeitouni NC, Oseroff AR, Shieh S. Photodynamic therapy for nonmelanoma skin cancers. Current review and update. Mol Immunol 2003; 39(17-18):1133-1136.
2. Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997; 79(12):2282-2308.
3. Frank J, Poh-Fitzpatrick MB, King LE Jr, Christiano AM. The genetic basis of "Scarsdale Gourmet Diet" variegate porphyria: a missense mutation in the protoporphyrinogen oxidase gene. Arch Dermatol Res 1998; 290(8):441-445.
4. Ponka P. Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood 1997; 89(1):1-25.
5. Gibson SL, Cupriks DJ, Havens JJ, Nguyen ML, Hilf R. A regulatory role for porphobilinogen deaminase (PBGD) in delta-aminolaevulinic acid (delta-ALA)-induced photosensitization? Br J Cancer 1998; 77(2):235-243.
6. Schoenfeld N, Mamet R, Leibovici L, Epstein O, Teitz Y, Atsmon A. Growth rate determines activity of porphobilinogen deaminase both in nonmalignant and malignant cell lines. Biochem Med Metab Biol 1988; 40(2):213-217.
7. Stummer W, Stocker S, Wagner S, Stepp H, Fritsch C, Goetz C, et al. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 1998; 42(3):518-525.
8. Stepp H, Sroka R, Baumgartner R. Fluorescence endoscopy of gastrointestinal diseases: basic principles, techniques, and clinical experience. Endoscopy 1998; 30(4):379-386.
9. Hinnen P, de Rooij FW, van Velthuysen ML, Edixhoven A, van Hillegersberg R, Tilanus HW, et al. Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: a study in patients with (pre)malignant lesions of the oesophagus. Br J Cancer 1998; 78(5):679-682.
10. Kriegmair M, Baumgartner R, Knuchel R, Stepp H, Hofstadter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 1996; 155(1):105-109.
11. Orenstein A, Kostenich G, Tsur H, Kogan L, Malik Z. Temperature monitoring during photodynamic therapy of skin tumors with topical 5-aminolevulinic acid application. Cancer Lett 1995; 93(2):227-232.
12. Orenstein A, Kostenich G, Roitman L, Shechtman Y, Kopolovic Y, Ehrenberg B, et al. A comparative study of tissue distribution and photodynamic therapy selectivity of chlorin e6, Photofrin II and ALA-induced protoporphyrin IX in a colon carcinoma model. Br J Cancer 1996; 73(8):937-944.
13. Orenstein A, Haik J, Tamir J, Winkler E, Trau H, Malik Z, et al. Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application. Dermatol Surg 2000; 26(8):765-769.
14. Wu SM, Ren QG, Zhou MO, Peng Q, Chen JY. Protoporphyrin IX production and its photodynamic effects on glioma cells, neuroblastoma cells and normal cerebellar granule cells in vitro with 5-aminolevulinic acid and its hexylester. Cancer Lett 2003; 200(2):123-131.
15. Nelson JS, Kimel S, Brown L, Berns MW. Glucose administration combined with photodynamic therapy of cancer improves therapeutic efficacy. Lasers Surg Med 1992; 12(2):153-158.
16. Pech O, Nagy CD, Gossner L, May A, Ell C. Photodynamic therapy of human Bar rett's cancer using 5-aminolaevulinic acid-induced protoporphyrin IX: an in vivo dosimetry study in athymic nude mice. Eur J Gastroenterol Hepatol 2002; 14(6):657-662.
17. Wyld L, Reed MW, Brown NJ. The influence of hypoxia and pH on aminolaevulinic acid-induced photodynamic therapy in bladder cancer cells in vitro. Br J Cancer 1998; 77(10):1621-1627.
18. Reddi E, Zhou C, Biolo R, Menegaldo E, Jori G. Liposome- or LDL-administered Zn (II)-phthalocyanine as a photodynamic agent for tumours. I. Pharmacokinetic properties and phototherapeutic efficiency. Br J Cancer 1990; 61(3):407-411.
19. Bhasin G, Kausar H, Athar M. Protoporphyrin-IX accumulation and cutaneous tumor regression in mice using a ferrochelatase inhibitor. Cancer Lett 2002; 187(1-2):9-16.
20. Sakai Tadashi. Biomarkers of lead exposure. Ind Health 2000; 38(2):127-142.
21. Taketani S, Kohno H, Kinoshita S, Tokunaga R. The effects of lead on differentiation of the Friend leukemia cells and rat bone marrow cells. Toxicol Appl Pharmacol 1985; 77(3):374-380.
22. Monkkonen J, Brown CS, Thompson TT, Heath TD. Liposome-mediated delivery of gallium to macrophage-like cells in vitro: demonstration of a transferrin-independent route for intracellular delivery of metal ions. Pharm Res 1993; 10(8):1130-1135.
23. Seligman PA, Moran PL, Schleicher RB, Crawford ED. Treatment with gallium nitrate: evidence for interference with iron metabolism in vivo. Am J Hematol 1992; 41(4):232-240.
24. Chitambar CR, Matthaeus WG, Antholine WE, Graff K, O'Brien WJ. Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea. Blood 1988; 72(6):1930-1936.
25. Goering PL, Rehm S. Inhibition of liver, kidney, and erythrocyte delta-aminolevulinic acid dehydratase (porphobilinogen synthase) by gallium in the rat. Environ Res 1990; 53(2):135-151.
26. Mauzerall D, Granick S. The occurrence and determination of delta-amino-levulinic acid and porphobilinogen in urine. J Biol Chem 1956; 219(1):435-446.
27. Bishop TR, Miller MW, Wang A, Dierks PM. Multiple copies of the ALA-D gene are located at the Lv locus in Mus domesticus mice. Genomics 1998; 48(2):221-231.
28. Rocha JB, Pereira ME, Emanuelli T, Christofari RS, Souza DO. Effect of treatment with mercury chloride and lead acetate during the second stage of rapid postnatal brain growth on delta-aminolevulinic acid dehydratase (ALA-D) activity in brain, liver, kidney and blood of suckling rats. Toxicology 1995; 100(1-3):27-37.
29. Polo CF, Afonso SG, Navone NM, Rossetti MV, del CBA. Zinc aminolevulinic acid dehydratase reactivation index as a tool for diagnosis of lead exposure. Ecotoxicol Environ Saf 1995; 32(3):267-272.
30. Christenson WR, Bestervelt LL, Piper WN. Evidence for pteridine regulation of lead-mediated inhibition of uroporphyrinogen and heme formation in rat bone marrow. Toxicol Appl Pharmacol 1992; 113(1):138-143.
31. Chretien S, Dubart A, Beaupain D, Raich N, Grandchamp B, Rosa J, et al. Alternative transcription and splicing of the human porphobilinogen deaminase gene result either in tissue-specific or in housekeeping expression. Proc Natl Acad Sci USA 1988; 85(1):6-10.
32. Guo GG, Gu M, Etlinger JD. 240-kDa proteasome inhibitor (CF-2) is identical to delta-aminolevulinic acid dehydratase. J Biol Chem 1994; 269(17):12399-12402.
33. Lu H, Guizzetti M, Costa LG. Inorganic lead stimulates DNA synthesis in human astrocytoma cells: role of protein kinase Calpha. J Neurochem 2001; 78(3):590-599.
34. Sieg DJ, Billings RE. Lead/cytokine-mediated oxidative DNA damage in cultured mouse hepatocytes. Toxicol Appl Pharmacol 1997; 142(1):106-115.